Previously Successful
The Canadian biotechnology company Hemostemix (TSXV:HEM; FRA:2VF0) is expanding its collaboration with a cardiology team from the Dominican Republic that has already successfully treated 200 patients with ACP-01 therapy in the past.
The treatments took place at the time as part of a study that was published in the scientific journal ‘Stem Cell Research and Therapy’. The participants were treated for atherosclerosis or enlargement of the heart walls (ischemic and non-ischemic dilated cardiomyopathy).
Patients Report Success of Treatment
These patients reported feeling better, having more energy, showing greater resilience, and experiencing an overall improvement in their quality of life. According to Hemostemix, ACP-01 showed remarkable results, increasing the ejection fraction by up to 47.1% in patients with dilated cardiomyopathy and by up to 27% in patients with ischemic cardiomyopathy, in patients with an ejection fraction of 20% or less.
The experienced heart specialists could now treat up to 110 patients per month. At a cost of $37,000 per ACP unit, the team can treat five times as many patients as currently projected for treatment.
